<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82572">
  <stage>Registered</stage>
  <submitdate>30/01/2008</submitdate>
  <approvaldate>13/02/2008</approvaldate>
  <actrnumber>ACTRN12608000079347</actrnumber>
  <trial_identification>
    <studytitle>Combination Therapy with Tiotropium in Chronic Obstructive Pulmonary Disease (COTTS)</studytitle>
    <scientifictitle>Combination therapy with  tiotropium and formoterol in moderate to severe Chronic Obstructive Pulmonary Disease: effects on exercise capacity and health related quality of life</scientifictitle>
    <utrn />
    <trialacronym>COTTS</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Airways Disease (COPD)</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>At the initial visit all subjects will be commenced on Tiotropium 18mcg daily via inhaler. Subjects will be randomised to receive either placebo or formoterol 12mcg bd via inhaler for 6 weeks. There will then be a 2 week washout period for formoterol (not Tiotropium). Subjects will then crossover to the alternate arm of therapy for a further 6 weeks.</interventions>
    <comparator>Tiotropium 18mcg daily via inhaler with additional placebo.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Exercise capacity and health related quality of life as measured by the St George's Respiratory Questionnaire (SGRQ).</outcome>
      <timepoint>End of active and placebo phase.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Symptoms, spirometry and the Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity (BODE) Index.</outcome>
      <timepoint>End of active and placebo phase.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Chronic Obstructive Airways Disease (COPD).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Myocardial infarction within 3 months of enrolment in the study.
Prostatism
Glaucoma</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/08/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Centre for Clinical Research and effective practice (CCRep)</primarysponsorname>
    <primarysponsoraddress>Private Bag 93311
Otahuhu
Auckland</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Auckland Medical Research Foundation</fundingname>
      <fundingaddress>PO Box 7151 
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Tiotropium (Spiriva) and formoterol (Oxis) are both currently available prescription medicines for people with COPD. Each of them has a particular effect on the airway. They are usually prescribed independently although it is quite possible for them to be prescribed together. Therefore some people with COPD may already be taking one or both of them. People participating in this study will take a regular dose of tiotropium plus a placebo for 6 weeks and a regular dose of tiotropium plus formoterol for 6 weeks. There will be 2 weeks between each 6 week period when participants will take only tiotropium.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern Y Ethics Committee</ethicname>
      <ethicaddress>PO Box 1031
Hamilton</ethicaddress>
      <ethicapprovaldate>16/03/2007</ethicapprovaldate>
      <hrec>NTY/06/09/079</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Lata Jayaram</name>
      <address>Respiratory Department
Middlemore Hospital
Private Bag 93311
Otahuhu
Auckland</address>
      <phone>+64 9 276 0044 extn 2951</phone>
      <fax />
      <email>JayaraL@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Andrew Nelson</name>
      <address>CCRep
Private Bag 93311
Otahuhu
Auckland</address>
      <phone>+64 9 276 0044 extn 2988</phone>
      <fax>+64 9 250 3878</fax>
      <email>NelsonA@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ruth Withers</name>
      <address>CCRep 
Private Bag 93311
Otahuhu
Auckland</address>
      <phone>+64 9 276 0044 extn 2967</phone>
      <fax>+64 9 250 3828</fax>
      <email>ruth.withers@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>